Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             157 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Active-specific immunization against melanoma: Is the problem at the receiving end? Monsurrò, Vladia
2003
6 p. 473-480
8 p.
artikel
2 Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine Hsueh, Eddy C
2003
6 p. 401-407
7 p.
artikel
3 Antigens in chronic lymphocytic leukemia—Implications for cell origin and leukemogenesis Rosén, Anders
2010
6 p. 400-409
10 p.
artikel
4 Anti-idiotypic monoclonal antibody cancer vaccines Chapman, Paul B.
1995
6 p. 367-374
8 p.
artikel
5 Augmenting the immunogenicity of carbohydrate tumor antigens Livingston, Philip O.
1995
6 p. 357-366
10 p.
artikel
6 Author index 1995 1995
6 p. I-
1 p.
artikel
7 Author Index and Keyword Index 2000
6 p. ix-xii
nvt p.
artikel
8 Autophagy in cancer: Having your cake and eating it Hoare, Matthew
2011
6 p. 397-404
8 p.
artikel
9 Burkitt lymphoma Klein, Eva
2009
6 p. 345-346
2 p.
artikel
10 Burkitt lymphoma—A stalking horse for cancer research? Klein, George
2009
6 p. 347-350
4 p.
artikel
11 Burkitt's lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology Rowe, Martin
2009
6 p. 377-388
12 p.
artikel
12 Cancer, aging and the optimal tissue design Komarova, Natalia L.
2005
6 p. 494-505
12 p.
artikel
13 CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells Deaglio, Silvia
2010
6 p. 416-423
8 p.
artikel
14 CD8+ T cell immunity to Epstein-Barr virus and Kaposi’s sarcoma-associated herpes virus Hislop, Andrew D.
2008
6 p. 416-422
7 p.
artikel
15 Cell transformation induced by Epstein–Barr virus—living dangerously Rowe, Martin
2001
6 p. 403-405
3 p.
artikel
16 Cellular senescence—A barrier against tumor development? Larsson, Lars-Gunnar
2011
6 p. 347-348
2 p.
artikel
17 Cellular senescence: A link between cancer and age-related degenerative disease? Campisi, Judith
2011
6 p. 354-359
6 p.
artikel
18 Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting Burger, Jan A.
2010
6 p. 424-430
7 p.
artikel
19 Circulating EBV DNA as a tumor marker for nasopharyngeal carcinoma Allen Chan, K.C
2002
6 p. 489-496
8 p.
artikel
20 Clinical and biological significance of HLA-G expression in ovarian cancer Sheu, Jim Jinn-Chyuan
2007
6 p. 436-443
8 p.
artikel
21 CLL-like monoclonal B-cell lymphocytosis: Are we all bound to have it? Scarfò, Lydia
2010
6 p. 384-390
7 p.
artikel
22 Commentary Klein, George
2002
6 p. 415-418
4 p.
artikel
23 Contents and index of volume 7, 1996 1996
6 p. i-xv
nvt p.
artikel
24 Contents of Volume 10 2000
6 p. i-viii
nvt p.
artikel
25 Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus Delecluse, Henri-Jacques
2008
6 p. 409-415
7 p.
artikel
26 Control of papillomavirus DNA replication and transcription Desaintes, Christian
1996
6 p. 339-347
9 p.
artikel
27 Current criteria to establish human carcinogens Cogliano, Vincent James
2004
6 p. 407-412
6 p.
artikel
28 Definition of tumor antigens suitable for vaccine construction Lewis, Jonathan J.
1995
6 p. 321-327
7 p.
artikel
29 Dendritic cells as vectors for immunotherapy of cancer Paczesny, Sophie
2003
6 p. 439-447
9 p.
artikel
30 Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration Andersen, Mads Hald
2003
6 p. 449-459
11 p.
artikel
31 Dynamics of colorectal cancer Michor, Franziska
2005
6 p. 484-493
10 p.
artikel
32 EBNA2 and Notch signalling in Epstein–Barr virus mediated immortalization of B lymphocytes Zimber-Strobl, Ursula
2001
6 p. 423-434
12 p.
artikel
33 EBV and genomic instability—A new look at the role of the virus in the pathogenesis of Burkitt's lymphoma Gruhne, Bettina
2009
6 p. 394-400
7 p.
artikel
34 Editorial Board 2008
6 p. CO2-
1 p.
artikel
35 Editorial Board 2007
6 p. CO2-
1 p.
artikel
36 Editorial Board 2009
6 p. CO2-
1 p.
artikel
37 Editorial Board 2010
6 p. CO2-
1 p.
artikel
38 Editorial Board 2011
6 p. CO2-
1 p.
artikel
39 Emergence and prevention of resistance against small molecule inhibitors Wodarz, Dominik
2005
6 p. 506-514
9 p.
artikel
40 Emerging concepts in tumor progression and therapy Classon, Marie
2000
6 p. 393-397
5 p.
artikel
41 Endemic Burkitt's lymphoma as a polymicrobial disease Chene, Arnaud
2009
6 p. 411-420
10 p.
artikel
42 Environmental and chemical carcinogenesis Wogan, Gerald N.
2004
6 p. 473-486
14 p.
artikel
43 Epidemiology of nasopharyngeal carcinoma Yu, Mimi C.
2002
6 p. 421-429
9 p.
artikel
44 Epigenetic alterations associated with cellular senescence: A barrier against tumorigenesis or a red carpet for cancer? Decottignies, Anabelle
2011
6 p. 360-366
7 p.
artikel
45 Epitope selection and development of peptide based vaccines to treat cancer Celis, Esteban
1995
6 p. 329-336
8 p.
artikel
46 Epstein–Barr virus and its role in the pathogenesis of Burkitt's lymphoma: An unresolved issue Bornkamm, Georg W.
2009
6 p. 351-365
15 p.
artikel
47 Epstein–Barr virus complementary strand transcripts (CSTs / BARTs) and cancer Smith, Paul
2001
6 p. 469-476
8 p.
artikel
48 Epstein-Barr virus evasion of CD8+ and CD4+ T cell immunity via concerted actions of multiple gene products Ressing, Maaike E.
2008
6 p. 397-408
12 p.
artikel
49 Epstein–Barr virus in the pathogenesis of NPC Raab-Traub, Nancy
2002
6 p. 431-441
11 p.
artikel
50 Estimation of mutation frequencies in normal mammalian cells and the development of cancer Turker, Mitchell S.
1998
6 p. 407-419
13 p.
artikel
51 Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells Speiser, Daniel E.
2003
6 p. 461-472
12 p.
artikel
52 Evolution and the inevitability of human cancer Simpson, Andrew J.G.
1998
6 p. 439-445
7 p.
artikel
53 Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses Rouas-Freiss, Nathalie
2007
6 p. 413-421
9 p.
artikel
54 Extracellular thioredoxin and thioredoxin-binding protein 2 in control of cancer Nakamura, Hajime
2006
6 p. 444-451
8 p.
artikel
55 Failsafe program escape and EMT: A deleterious partnership Ansieau, Stéphane
2011
6 p. 392-396
5 p.
artikel
56 Familial nasopharyngeal carcinoma Zeng, Yi-Xin
2002
6 p. 443-450
8 p.
artikel
57 Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects Prendergast, George C
2000
6 p. 443-452
10 p.
artikel
58 Genetic alterations and DNA repair in human carcinogenesis Dixon, Kathleen
2004
6 p. 441-448
8 p.
artikel
59 Genetic and epigenetic changes in nasopharyngeal carcinoma Lo, Kwok-Wai
2002
6 p. 451-462
12 p.
artikel
60 Genetic instability in cancer: Theory and experiment Beckman, Robert A.
2005
6 p. 423-435
13 p.
artikel
61 Genetic variation and risk of chronic lymphocytic leukaemia Crowther-Swanepoel, Dalemari
2010
6 p. 363-369
7 p.
artikel
62 Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors Blachere, Nathalie E.
1995
6 p. 349-355
7 p.
artikel
63 Heterogeneity of papillomaviruses Myers, Gerald
1996
6 p. 349-358
10 p.
artikel
64 HLA control in the progression of human papillomavirus infections Breitburd, Françoise
1996
6 p. 359-371
13 p.
artikel
65 HLA-G and cancer Carosella, Edgardo D.
2007
6 p. 411-412
2 p.
artikel
66 HLA-G expression in malignant melanoma Rebmann, Vera
2007
6 p. 422-429
8 p.
artikel
67 HLA-G in B-chronic lymphocytic leukaemia: Clinical relevance and functional implications Rebmann, Vera
2007
6 p. 430-435
6 p.
artikel
68 HLA-G in the skin—Friend or foe? Urosevic, Mirjana
2007
6 p. 480-484
5 p.
artikel
69 How does Epstein–Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? Allday, Martin J.
2009
6 p. 366-376
11 p.
artikel
70 Human papillomaviruses in non-melanoma skin cancer de Villiers, Ethel-Michele
1999
6 p. 413-422
10 p.
artikel
71 Human papillomavirus life cycle: active and latent phases Stubenrauch, Frank
1999
6 p. 379-386
8 p.
artikel
72 Human papillomavirus vaccines Breitburd, Françoise
1999
6 p. 431-445
15 p.
artikel
73 Hypermutability and silent mutations in human carcinogenesis Strauss, Bernard S.
1998
6 p. 431-438
8 p.
artikel
74 Identification of EBV transforming genes by recombinant EBV technology Izumi, Kenneth M.
2001
6 p. 407-414
8 p.
artikel
75 Immortalization of human cells and their malignant conversion by high risk human papillomavirus genotypes zur Hausen, Harald
1999
6 p. 405-411
7 p.
artikel
76 Immune escape by Epstein–Barr virus associated malignancies Münz, Christian
2008
6 p. 381-387
7 p.
artikel
77 Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis Liang, Chengyu
2008
6 p. 423-436
14 p.
artikel
78 Immune-refractory cancers and their little helpers—An extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? Wischhusen, Jörg
2007
6 p. 459-468
10 p.
artikel
79 Immunotherapy of melanoma Parmiani, Giorgio
2003
6 p. 391-400
10 p.
artikel
80 Immunotherapy of melanoma: the good news, the bad ones and what to do next Marincola, Francesco M.
2003
6 p. 387-389
3 p.
artikel
81 Infectious agents and cancer: criteria for a causal relation Pagano, Joseph S.
2004
6 p. 453-471
19 p.
artikel
82 Inflammation as a tumor promoter in cancer induction Philip, Mary
2004
6 p. 433-439
7 p.
artikel
83 Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015 McCormick, Frank
2000
6 p. 453-459
7 p.
artikel
84 Interactions of the human papillomavirus E7 protein with cell cycle regulators Jones, D.Leanne
1996
6 p. 327-337
11 p.
artikel
85 Interferon regulatory factor 7: a key cellular mediator of LMP-1 in EBV latency and transformation Zhang, Luwen
2001
6 p. 445-453
9 p.
artikel
86 Introduction Simpson, Andrew J.G.
1998
6 p. 403-405
3 p.
artikel
87 Introduction de Villiers, Ethel-Michele
1999
6 p. 377-
1 p.
artikel
88 Introduction: Cancer vaccines Livingston, Philip O.
1995
6 p. 319-320
2 p.
artikel
89 Introduction: Human papillomavirus Thierry, Françoise
1996
6 p. 307-
1 p.
artikel
90 Introduction: nasopharyngeal cancer Huang, Dolly P
2002
6 p. 419-
1 p.
artikel
91 LMP1 structure and signal transduction Eliopoulos, Aristides G
2001
6 p. 435-444
10 p.
artikel
92 Local delivery of poxvirus vaccines for melanoma Hörig, Heidi
2003
6 p. 417-422
6 p.
artikel
93 Manipulation of the immune response by Epstein–Barr virus and Kaposi's sarcoma-associated herpesvirus: Consequences for tumor development Ressing, Maaike E.
2008
6 p. 379-380
2 p.
artikel
94 Matrix metalloproteinases in tumor invasion and metastasis Stamenkovic, Ivan
2000
6 p. 415-433
19 p.
artikel
95 Mechanism of HPV E6 proteins in cellular transformation Huibregtse, Jon M.
1996
6 p. 317-326
10 p.
artikel
96 MicroRNAs of Kaposi's sarcoma-associated herpes virus Ganem, Don
2008
6 p. 437-440
4 p.
artikel
97 Modern criteria to determine the etiology of human carcinogens Mossman, Brooke T.
2004
6 p. 449-452
4 p.
artikel
98 Modern criteria to establish human cancer etiology Carbone, Michele
2004
6 p. 397-398
2 p.
artikel
99 Molecular basis of CLL Pekarsky, Yuri
2010
6 p. 370-376
7 p.
artikel
100 Motexafin gadolinium: A novel redox active drug for cancer therapy Magda, Darren
2006
6 p. 466-476
11 p.
artikel
101 Multiple roles of LMP1 in Epstein-Barr virus induced immune escape Middeldorp, J.M.
2008
6 p. 388-396
9 p.
artikel
102 Multistep and multifactorial carcinogenesis: when does a contributing factor become a carcinogen? Carbone, Michele
2004
6 p. 399-405
7 p.
artikel
103 Multistep skin cancer in mice as a model to study the evolution of cancer cells Kemp, Christopher J.
2005
6 p. 460-473
14 p.
artikel
104 Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy Lee, Steven P
2002
6 p. 463-471
9 p.
artikel
105 Natural selection in neoplastic progression of Barrett's esophagus Maley, Carlo C.
2005
6 p. 474-483
10 p.
artikel
106 New aspects of integrin signaling in cancer Parise, Leslie V
2000
6 p. 407-414
8 p.
artikel
107 New insights into the pathogenesis of chronic lymphocytic leukemia Klein, Ulf
2010
6 p. 377-383
7 p.
artikel
108 [No title] Wodarz, D.
2005
6 p. 421-422
2 p.
artikel
109 Novel gene therapy approach for nasopharyngeal carcinoma Liu, Fei-Fei
2002
6 p. 505-515
11 p.
artikel
110 Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence Larsson, Lars-Gunnar
2011
6 p. 367-376
10 p.
artikel
111 On the origin of multiple mutations in human cancers Jackson, Aimee L.
1998
6 p. 421-429
9 p.
artikel
112 On the potential of thioredoxin reductase inhibitors for cancer therapy Urig, Sabine
2006
6 p. 452-465
14 p.
artikel
113 Papillomaviruses in non-melanoma skin cancer: epidemiological aspects Kiviat, Nancy B.
1999
6 p. 397-403
7 p.
artikel
114 Papillomavirus-like particles and HPV vaccine development Schiller, John T.
1996
6 p. 373-382
10 p.
artikel
115 Peptide vaccine trials for melanoma: preclinical background and clinical results Talebi, Tony
2003
6 p. 431-438
8 p.
artikel
116 Proof for EBV's sustaining role in Burkitt's lymphomas Vereide, David
2009
6 p. 389-393
5 p.
artikel
117 Rational peptide-based tumour vaccine development and T cell monitoring Scheibenbogen, Carmen
2003
6 p. 423-429
7 p.
artikel
118 Restricted expression of EBV encoded proteins in in vitro infected CLL cells Klein, Eva
2010
6 p. 410-415
6 p.
artikel
119 Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine® Sondak, Vernon K
2003
6 p. 409-415
7 p.
artikel
120 Role and limitations of epidemiology in establishing a causal association Franco, Eduardo L.
2004
6 p. 413-426
14 p.
artikel
121 Role of EBV in microRNA dysregulation in Burkitt lymphoma De Falco, Giulia
2009
6 p. 401-406
6 p.
artikel
122 Role of LMP1 in immune control of EBV infection Pai, Saparna
2001
6 p. 455-460
6 p.
artikel
123 Role of telomeres and telomerase in cancer Shay, Jerry W.
2011
6 p. 349-353
5 p.
artikel
124 Selection of potent immunological adjuvants for vaccine construction McElrath, Margaret Juliana
1995
6 p. 375-385
11 p.
artikel
125 Selective evolutionary pressure from the tissue microenvironment drives tumor progression Smalley, Keiran S.M.
2005
6 p. 451-459
9 p.
artikel
126 Senescence and pre-malignancy: How do tumors progress? Saab, Raya
2011
6 p. 385-391
7 p.
artikel
127 Signalling events regulating lymphoid growth and survival Brennan, Paul
2001
6 p. 415-421
7 p.
artikel
128 Soluble HLA-G: Are they clinically relevant? Pistoia, Vito
2007
6 p. 469-479
11 p.
artikel
129 Somatic evolution of cancer cells Boland, C. Richard
2005
6 p. 436-450
15 p.
artikel
130 Structure, expression and function of HLA-G in renal cell carcinoma Seliger, Barbara
2007
6 p. 444-450
7 p.
artikel
131 Subject index 1995 1995
6 p. III-VIII
nvt p.
artikel
132 Targeting tumor vasculature with homing peptides from phage display Ruoslahti, Erkki
2000
6 p. 435-442
8 p.
artikel
133 T-cell function in chronic lymphocytic leukaemia Riches, John C.
2010
6 p. 431-438
8 p.
artikel
134 Telomerase and human tumorigenesis Stewart, Sheila A.
2000
6 p. 399-406
8 p.
artikel
135 The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia Galloway, Denise A.
1996
6 p. 309-315
7 p.
artikel
136 The epigenetics of cancer etiology Feinberg, Andrew P.
2004
6 p. 427-432
6 p.
artikel
137 The interaction between p53 and papillomaviruses Mantovani, Fiamma
1999
6 p. 387-395
9 p.
artikel
138 The Myc/macrophage tango: Oncogene-induced senescence, Myc style Lee, Soyoung
2011
6 p. 377-384
8 p.
artikel
139 The next wave of recombinant and synthetic anticancer vaccines Irvine, Kari R.
1995
6 p. 337-347
11 p.
artikel
140 The role of EBERs in oncogenesis Takada, Kenzo
2001
6 p. 461-467
7 p.
artikel
141 The role of HLA-G in gastrointestinal inflammatory disease and malignancy Downs-Kelly, Erinn
2007
6 p. 451-458
8 p.
artikel
142 The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia Packham, Graham
2010
6 p. 391-399
9 p.
artikel
143 The serological response to papillomaviruses Dillner, Joakim
1999
6 p. 423-430
8 p.
artikel
144 The significance of LMP1 expression in nasopharyngeal carcinoma Tsao, Sai Wah
2002
6 p. 473-487
15 p.
artikel
145 The thioredoxin system in cancer Arnér, Elias S.J.
2006
6 p. 420-426
7 p.
artikel
146 The thioredoxin system in cancer—introduction to a thematic volume of Seminars in Cancer Biology Arnér, Elias S.J.
2006
6 p. 419-
1 p.
artikel
147 The use of genetic instability as a clinical tool for cancer diagnosis Bevilacqua, Roberta A.U.
1998
6 p. 447-453
7 p.
artikel
148 Thioredoxin and protein kinases in redox signaling Fujino, Go
2006
6 p. 427-435
9 p.
artikel
149 Thioredoxin in cancer—Role of histone deacetylase inhibitors Marks, Paul A.
2006
6 p. 436-443
8 p.
artikel
150 To the genesis of Burkitt lymphoma: Regulation of apoptosis by EBNA-1 and SAP may determine the fate of Ig-myc translocation carrying B lymphocytes Nagy, Noemi
2009
6 p. 407-410
4 p.
artikel
151 Treatment strategy and clinical experience Teo, Peter M.L
2002
6 p. 497-504
8 p.
artikel
152 Viral and cellular MARCH ubiquitin ligases and cancer Wang, Xiaoli
2008
6 p. 441-450
10 p.
artikel
153 Volume and contents of volume 8, 1998 1998
6 p. i-xv
nvt p.
artikel
154 Volume Contents and Index 1999
6 p. i-xii
nvt p.
artikel
155 Volume contents, Auhtor and Keywords 2002
6 p. I-X
nvt p.
artikel
156 Volume Contents, Author and Keyword Indexes 2003
6 p. I-XI
nvt p.
artikel
157 Where is the biology of CLL leading us? Caligaris-Cappio, Federico
2010
6 p. 361-362
2 p.
artikel
                             157 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland